immunogenicity


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to immunogenicity: humoral immunity

im·mu·no·gen·ic

 (ĭm′yə-nō-jĕn′ĭk, ĭ-myo͞o′-)
adj.
Capable of inducing an immune response.

im′mu·no·ge·nic′i·ty (-jə-nĭs′ĭtē)

immunogenicity

(ˌɪmjʊnəʊdʒɪˈnɪsɪtɪ)
n
the state of being immunogenic
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.immunogenicity - the property of eliciting an immune response
immunity, resistance - (medicine) the condition in which an organism can resist disease
References in periodicals archive ?
Hookipa Biotech AG, a company pioneering a new class of immunotherapies for oncology and infectious diseases, today presented the un-blinded safety and immunogenicity data through month four from the Company's phase 1 first-in-human trial of HB-101, a vaccine against human cytomegalovirus (CMV), based on Hookipa's proprietary Vaxwave0 platform.
Immunogenicity is now known to be one of the main causes of this loss of response.
US-based drug development decision support technology and consulting services company Certara is launching a Quantitative Systems Pharmacology Immunogenicity Consortium, the company said.
In this Phase III, open-label study, we assessed the immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine (Fluarix[TM] Tetra) in Brazilian adults (NCT02369341).
The mechanisms for the development of response failure are complex; however, immunogenicity of these protein-based TNF antagonists has been recognized as a major factor (5).
Use of an immunomodulatory agent can reduce the risk of immunogenicity and improve clinical response.
It also brings on board IPM's immunogenicity, pharmacokinetics, and pharmacodynamics expertise to complement BioAgilytix's capabilities in biomarkers, cell-based assays, and immunogenicity and pharmacokinetics.
IPM Biotech is specialised in large molecule bioanalysis, particularly in the area of immunogenicity.
Immunogenicity continues to be a major concern for the field of science, due to its impact on safety and efficacy.
PROPOSED REVISIONS TO THE GUIDELINE ON THE ASSESSMENT OF IMMUNOGENICITY FOR BIOTECHNOLOGY DERIVED PROTEINS AND ITS RELEVANCE TO BIOSIMILARS
Antitope Limited, an Abzena company, has collaborated with Synthon Biopharmaceuticals BV (Synthon), a global pharmaceutical company with expertise in the development of complex small molecule and biosimilar drugs and new biopharmaceuticals, including antibody drug conjugates (ADC), to assess the potential immunogenicity of candidate antibodies for Synthon's ADC programmes.